Patents Represented by Attorney, Agent or Law Firm Gail M. Kempler
  • Multifunctional chimeric neurotrophic factors
    Patent number: 5488099
    Abstract: Neurotrophins having activities of multiple parental neurotrophins are described, as well as DNA for their production and pharmaceutical preparations thereof.
    Type: Grant
    Filed: November 20, 1992
    Date of Patent: January 30, 1996
    Inventors: Hakan B. Persson, deceased, Carlos F. I. Moliner
  • CNTF and IL-6 antagonists
    Patent number: 5470952
    Abstract: Heterodimer proteins comprising a soluble .alpha. specificity determining cytokine receptor component and the extracellular domain of a .beta. receptor component function as CNTF and IL-6 antagonsists.
    Type: Grant
    Filed: October 20, 1993
    Date of Patent: November 28, 1995
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, Aris N. Economides, George D. Yancopoulos
  • Assay system for degenerative muscle disease
    Patent number: 5360740
    Abstract: An assay system useful for detecting denervated or degenerating muscle by measuring the amount of soluble ciliary neurotrophic factor receptor in body fluids is described.
    Type: Grant
    Filed: July 2, 1992
    Date of Patent: November 1, 1994
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Nancy Y. Ip, Peter S. DiStefano, Neil Stahl
  • Nerve growth factor having altered receptor binding specificities
    Patent number: 5349055
    Abstract: A method of altering the receptor binding properties and the stability of neurotrophic factors is set forth. Mutant neurotrophic factors having altered receptor binding specificities are described. Specific embodiments include neurotrophic factors that bind trk receptors but do not bind to the low affinity NGF receptor.
    Type: Grant
    Filed: March 6, 1992
    Date of Patent: September 20, 1994
    Inventors: Hakan B. Persson, Carlos F. I. Moliner
  • Prevention of ES cell differentiation by ciliary neurotrophic factor
    Patent number: 5332672
    Abstract: The present invention provides for a stable, biologically active CNTF/receptor complex, and hybrids or routants thereof. The invention is also based in part on the discovery that the CNTF/receptor complex promotes differentiation through a signal transduction pathway on target cells that do not express the CNTF receptor. The invention further provides for a specific CNTFR mutant that promotes signal transduction without binding CNTF. The invention also provides for a CNTF/receptor blocking mutant, a mutant possessing a high binding affinity to CNTF, but possessing no signal transducing function. The present invention also identifies receptor components shared by the IL-6, CNTF, LIF and OSM signal transduction pathways, and the initiation of signal transduction based upon the presence of such components.
    Type: Grant
    Filed: April 9, 1992
    Date of Patent: July 26, 1994
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Joanne Conover, George D. Yancopoulos